RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates

Summary of Key Points Core Viewpoint - RxSight, Inc. reported a quarterly loss of $0.08 per share, which was better than the Zacks Consensus Estimate of a loss of $0.10, marking an earnings surprise of +20.00% [1] - The company has shown mixed performance in terms of revenue and earnings estimates over the past year, with a significant decline in stock price [3][4] Financial Performance - For the quarter ended June 2025, RxSight posted revenues of $33.64 million, slightly surpassing the Zacks Consensus Estimate by 0.11%, but down from $34.89 million a year ago [2] - Over the last four quarters, the company has exceeded consensus revenue estimates four times [2] Stock Performance and Outlook - RxSight shares have decreased approximately 78% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $29.04 million, and for the current fiscal year, it is -$0.49 on revenues of $126.63 million [7] Industry Context - The Medical - Instruments industry, to which RxSight belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of RxSight's stock may be influenced by the overall outlook of the industry [8]